Early Morning Watch List: Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX).

New York, NY -- (SBWIRE) -- 01/29/2013 -- Growing Stock Report iniates an Early Morning Watch List for the following stocks: Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) as of this writing, down (-24.56%) in pre-market.

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) a biopharmaceutical company tht focuses on discovering, developing, and commercializing small-molecule therapeutics derived from boron chemistry platform announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed that affects ~ 35 million people in the United States. According to TheStreet Anacor Pharmaceuticals' (ANAC) toenail fungus therapy tavaborole achieved the "complete cure" goal of a phase III study but the drug's efficacy appears to be inferior to a competing drug from Valeant Pharmaceuticals International, Inc. (NYSE:VRX) and only on par with a currently approved treatment.

Click Here to See What Other Investors are Saying About Anacor Pharmaceuticals, Inc.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) as of this writing, up (+17.87%) in pre-market.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) a biopharmaceutical company that focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States yesterday reported successful top-line results from the long-term Phase 3 study of Zerenex, its ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients suffering from end-stage renal disease on dialysis. In this evaluatin, Zerenex attained the study’s primary endpoint, indicating a highly statistically significant change in serum phosphorus compared with placebo over the four-week Efficacy Assessment Period of the study. Also, Zerenex met the key secondary endpoints of increasing ferritin and transferrin saturation and reducing the use of intravenous iron and erythropoiesis-stimulating agents versus the active control over the 52-week Safety Assessment Period of the evaluation. This long-term study was the final step of the firm’s Phase 3 registration program, which was conducted pursuant to a Special Protocol Assessment with the FDA. Yesterday Shares closed up 76.68 percent on the day at $6.06, and have been traded in a 52-week range of $1.28 to $5.19.

Pre-Market Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) is trading at $7.15

Click Here to See What Other Investors are Saying About Keryx Biopharmaceuticals Inc.

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure
GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com